KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	bevacizumab + PCM-075 Sensitive: C2 – Inclusion Criteria bevacizumab + PCM-075 Sensitive : C2	bevacizumab + PCM-075 Sensitive: C2 – Inclusion Criteria bevacizumab + PCM-075 Sensitive : C2
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	nivolumab + rigosertib Sensitive: C2 – Inclusion Criteria nivolumab + rigosertib Sensitive : C2	nivolumab + rigosertib Sensitive: C2 – Inclusion Criteria nivolumab + rigosertib Sensitive : C2
AR-V7 mutation	Prostate Cancer	AR-V7 mutation	Prostate Cancer	PCM-075 Sensitive: C3 – Early Trials PCM-075 Sensitive : C3	PCM-075 Sensitive: C3 – Early Trials PCM-075 Sensitive : C3
AR T878A	Prostate Cancer	AR T878A	Prostate Cancer	PCM-075 Sensitive: C3 – Early Trials PCM-075 Sensitive : C3	PCM-075 Sensitive: C3 – Early Trials PCM-075 Sensitive : C3
AR mutation	Prostate Cancer	AR mutation	Prostate Cancer	PCM-075 Sensitive: C3 – Early Trials PCM-075 Sensitive : C3	PCM-075 Sensitive: C3 – Early Trials PCM-075 Sensitive : C3
CCNE1 amplification	Ovarian Cancer	CCNE1 amplification	Ovarian Cancer	NBL-001 Sensitive: C3 – Early Trials NBL-001 Sensitive : C3	NBL-001 Sensitive: C3 – Early Trials NBL-001 Sensitive : C3
KRAS G13D	Colorectal Cancer	KRAS G13D	Colorectal Cancer	bevacizumab + PCM-075 Sensitive: C3 – Early Trials bevacizumab + PCM-075 Sensitive : C3	bevacizumab + PCM-075 Sensitive: C3 – Early Trials bevacizumab + PCM-075 Sensitive : C3
KRAS G12V	Colorectal Cancer	KRAS G12V	Colorectal Cancer	bevacizumab + PCM-075 Sensitive: C3 – Early Trials bevacizumab + PCM-075 Sensitive : C3	bevacizumab + PCM-075 Sensitive: C3 – Early Trials bevacizumab + PCM-075 Sensitive : C3
KRAS G12D	Colorectal Cancer	KRAS G12D	Colorectal Cancer	bevacizumab + PCM-075 Sensitive: C3 – Early Trials bevacizumab + PCM-075 Sensitive : C3	bevacizumab + PCM-075 Sensitive: C3 – Early Trials bevacizumab + PCM-075 Sensitive : C3
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	bevacizumab + PCM-075 Sensitive: C3 – Early Trials bevacizumab + PCM-075 Sensitive : C3	bevacizumab + PCM-075 Sensitive: C3 – Early Trials bevacizumab + PCM-075 Sensitive : C3
KRAS G12D	Non Small Cell Lung Cancer	KRAS G12D	Non Small Cell Lung Cancer	nivolumab + rigosertib Sensitive: C3 – Early Trials nivolumab + rigosertib Sensitive : C3	nivolumab + rigosertib Sensitive: C3 – Early Trials nivolumab + rigosertib Sensitive : C3
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	nivolumab + rigosertib Sensitive: C3 – Early Trials nivolumab + rigosertib Sensitive : C3	nivolumab + rigosertib Sensitive: C3 – Early Trials nivolumab + rigosertib Sensitive : C3
KRAS G12V	Non Small Cell Lung Cancer	KRAS G12V	Non Small Cell Lung Cancer	nivolumab + rigosertib Sensitive: C3 – Early Trials nivolumab + rigosertib Sensitive : C3	nivolumab + rigosertib Sensitive: C3 – Early Trials nivolumab + rigosertib Sensitive : C3
PIK3CD expression	Mantle Cell Lymphoma	PIK3CD expression	Mantle Cell Lymphoma	NBL-001 Sensitive: D – Preclinical NBL-001 Sensitive : D	NBL-001 Sensitive: D – Preclinical NBL-001 Sensitive : D
NRAS mutation	Non Small Cell Lung Cancer	NRAS mutation	Non Small Cell Lung Cancer	NBL-001 + ERAS-254 Sensitive: D – Preclinical NBL-001 + ERAS-254 Sensitive : D	NBL-001 + ERAS-254 Sensitive: D – Preclinical NBL-001 + ERAS-254 Sensitive : D
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	rigosertib Sensitive: D – Preclinical rigosertib Sensitive : D	rigosertib Sensitive: D – Preclinical rigosertib Sensitive : D
NRAS mutation	Colorectal Cancer	NRAS mutation	Colorectal Cancer	rigosertib Sensitive: D – Preclinical rigosertib Sensitive : D	rigosertib Sensitive: D – Preclinical rigosertib Sensitive : D
PLK1 overexpression	Colorectal Cancer	PLK1 overexpression	Colorectal Cancer	Immunotherapy + PLK1 inhibitor Sensitive: D – Preclinical Immunotherapy + PLK1 inhibitor Sensitive : D	Immunotherapy + PLK1 inhibitor Sensitive: D – Preclinical Immunotherapy + PLK1 inhibitor Sensitive : D
PIK3CG expression	Mantle Cell Lymphoma	PIK3CG expression	Mantle Cell Lymphoma	NBL-001 Sensitive: D – Preclinical NBL-001 Sensitive : D	NBL-001 Sensitive: D – Preclinical NBL-001 Sensitive : D
PIK3CG expression	Mantle Cell Lymphoma	PIK3CG expression	Mantle Cell Lymphoma	copanlisib + NBL-001 Sensitive: D – Preclinical copanlisib + NBL-001 Sensitive : D	copanlisib + NBL-001 Sensitive: D – Preclinical copanlisib + NBL-001 Sensitive : D
PIK3CD expression	Mantle Cell Lymphoma	PIK3CD expression	Mantle Cell Lymphoma	copanlisib + NBL-001 Sensitive: D – Preclinical copanlisib + NBL-001 Sensitive : D	copanlisib + NBL-001 Sensitive: D – Preclinical copanlisib + NBL-001 Sensitive : D
PIK3CB expression	Mantle Cell Lymphoma	PIK3CB expression	Mantle Cell Lymphoma	NBL-001 Sensitive: D – Preclinical NBL-001 Sensitive : D	NBL-001 Sensitive: D – Preclinical NBL-001 Sensitive : D
PIK3CB expression	Mantle Cell Lymphoma	PIK3CB expression	Mantle Cell Lymphoma	copanlisib + NBL-001 Sensitive: D – Preclinical copanlisib + NBL-001 Sensitive : D	copanlisib + NBL-001 Sensitive: D – Preclinical copanlisib + NBL-001 Sensitive : D
PIK3CA expression	Mantle Cell Lymphoma	PIK3CA expression	Mantle Cell Lymphoma	copanlisib + NBL-001 Sensitive: D – Preclinical copanlisib + NBL-001 Sensitive : D	copanlisib + NBL-001 Sensitive: D – Preclinical copanlisib + NBL-001 Sensitive : D
PIK3CA expression	Mantle Cell Lymphoma	PIK3CA expression	Mantle Cell Lymphoma	NBL-001 Sensitive: D – Preclinical NBL-001 Sensitive : D	NBL-001 Sensitive: D – Preclinical NBL-001 Sensitive : D
CDH1 expression	Non Small Cell Lung Cancer	CDH1 expression	Non Small Cell Lung Cancer	NBL-001 Resistant: D – Preclinical NBL-001 Resistant : D	NBL-001 Resistant: D – Preclinical NBL-001 Resistant : D
CCNA2 expression	Gastric Cancer	CCNA2 expression	Gastric Cancer	NBL-001 Sensitive: D – Preclinical NBL-001 Sensitive : D	NBL-001 Sensitive: D – Preclinical NBL-001 Sensitive : D
CCNA2 expression	Gastric Cancer	CCNA2 expression	Gastric Cancer	BI2536 Sensitive: D – Preclinical BI2536 Sensitive : D	BI2536 Sensitive: D – Preclinical BI2536 Sensitive : D
MCL1 underexpression	T Acute Lymphoblastic Leukemia	MCL1 underexpression	T Acute Lymphoblastic Leukemia	venetoclax + NBL-001 Sensitive: D – Preclinical venetoclax + NBL-001 Sensitive : D	venetoclax + NBL-001 Sensitive: D – Preclinical venetoclax + NBL-001 Sensitive : D
MYC underexpression	T Acute Lymphoblastic Leukemia	MYC underexpression	T Acute Lymphoblastic Leukemia	venetoclax + NBL-001 Sensitive: D – Preclinical venetoclax + NBL-001 Sensitive : D	venetoclax + NBL-001 Sensitive: D – Preclinical venetoclax + NBL-001 Sensitive : D
PIK3CA E545K	Squamous Cell Carcinoma of Head and Neck	PIK3CA E545K	Squamous Cell Carcinoma of Head and Neck	rigosertib Sensitive: D – Preclinical rigosertib Sensitive : D	rigosertib Sensitive: D – Preclinical rigosertib Sensitive : D
BCL2L1 underexpression	T Acute Lymphoblastic Leukemia	BCL2L1 underexpression	T Acute Lymphoblastic Leukemia	venetoclax + NBL-001 Sensitive: D – Preclinical venetoclax + NBL-001 Sensitive : D	venetoclax + NBL-001 Sensitive: D – Preclinical venetoclax + NBL-001 Sensitive : D

PLK1 inhibitor

PLK1 inhibitor

Associations(40)

Associations
(40)